文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

PORTEC-4a试验中阴道近距离放疗的质量保证

Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer.
PubMed 文献 · Radiother Oncol · 2020-11-05

PORTEC-4a试验评估分子整合风险谱指导的子宫内膜癌辅助治疗,其质量保证方案包括激活前虚拟运行和年度质量保证。虚拟运行中21家机构有15家(71.4%)需调整勾画或计划,调整后阴道顶端平均剂量从100.7%降至99.9%,范围和标准差收窄;年度质量保证中27例有5例(18.5%)重大偏差,多数偏差与勾画、阴道顶端剂量或参考体积长度相关。

要点

  • 虚拟运行中71.4%机构需调整勾画或计划,调整后剂量分布更集中。
  • 年度质量保证中18.5%病例存在重大偏差,多与勾画和剂量相关。
  • 年度质量保证对促进方案依从性和保障近距离放疗质量至关重要。

核心结论

  • 年度质量保证对促进方案依从性和确保各参与机构高质量阴道近距离放疗至关重要。

研究设计与样本

  • PORTEC-4a试验的质量保证方案包括激活前虚拟运行和年度质量保证,由近距离放疗专家组按检查表评审计划。

主要发现

  • 虚拟运行中21家机构有15家(71.4%)需调整勾画或计划。
  • 调整后阴道顶端平均剂量从100.7%降至99.9%,范围从83.6-135.1收窄至96.4-101.4,标准差从8.8降至1.1。
  • 年度质量保证中27例有22例(81.5%)无或轻微偏差,5例(18.5%)重大偏差。
  • 多数偏差与勾画、阴道顶端平均剂量(98.0%,74.7-114.2,标准差7.6)或参考体积长度相关。

关键数值与推荐

  • 协议规定阴道顶端平均剂量为100%(7 Gy)。

临床怎么用

  • 参与机构应执行虚拟运行和年度质量保证,重点关注勾画、阴道顶端剂量和参考体积长度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The PORTEC-4a trial investigates molecular-integrated risk profile guided adjuvant treatment for endometrial cancer. The quality assurance programme included a dummy run for vaginal brachytherapy prior to site activation, and annual quality assurance to verify protocol adherence. Aims of this study were to evaluate vaginal brachytherapy quality and protocol adherence. METHODS: For the dummy run, institutes were invited to create a brachytherapy plan on a provided CT-scan with the applicator in situ. For annual quality assurance, institutes provided data of one randomly selected brachytherapy case. A brachytherapy panel reviewed and scored the brachytherapy plans according to a checklist. RESULTS: At the dummy run, 15 out of 21 (71.4%) institutes needed adjustments of delineation or planning. After adjustments, the mean dose at the vaginal apex (protocol: 100%; 7 Gy) decreased from 100.7% to 99.9% and range and standard deviation (SD) narrowed from 83.6-135.1 to 96.4-101.4 and 8.8 to 1.1, respectively. At annual quality assurance, 22 out of 27 (81.5%) cases had no or minor and 5 out of 27 (18.5%) major deviations. Most deviations were related to delineation, mean dose at the vaginal apex (98.0%, 74.7-114.2, SD 7.6) or reference volume length. CONCLUSIONS: Most feedback during the brachytherapy quality assurance procedure of the PORTEC-4a trial was related to delineation, dose at the vaginal apex and the reference volume length. Annual quality assurance is essential to promote protocol compliance, ensuring high quality vaginal brachytherapy in all participating institutes.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Wortman BG, Astreinidou E, Laman MS, et al. Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer. Radiother Oncol. 2020. PMID: 33159971. doi:10.1016/j.radonc.2020.10.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。